ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical Practice Guidelines to include ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin/BCG. This update adds a recommendation for patients with BCG-unresponsive non-muscle invasive bladder cancer/NMIBC who have papillary-only disease. Previously, the guidelines recognized the combination only for patients with carcinoma in situ/CIS, but this expansion acknowledges the regimen’s long-term effectiveness and safety for a broader patient population.
The treatment is a first-in-class IL-15 receptor agonist designed to activate the body’s natural killer cells and T cells to target cancer. By mimicking natural biological properties, the therapy aims to overcome tumor resistance and establish immune memory, leading to more durable responses. While the NCCN’s inclusion of papillary-only disease is a Category 2A recommendation, the company noted that this specific use is not yet part of the current FDA-approved indication, which currently focuses on CIS patients.
Dr. Patrick Soon-Shiong, Founder and Chief Scientific Officer of ImmunityBio Inc. (NASDAQ:IBRX), described the update as a major milestone for patients who have exhausted standard options. The company is currently awaiting further FDA review regarding the papillary-only indication. In the meantime, ANKTIVA remains commercially available for its approved uses, backed by insurance coverage for over 100 million patients in the US and a permanent J-code for simplified reimbursement.
ImmunityBio Inc. (NASDAQ:IBRX) is a healthcare company that innovates, develops, and commercializes next-gen immunotherapies for activating the patient’s immune system and delivering protection against cancer and infectious diseases.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
